Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | PRKCQ | Q04759 | 6/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.49 |
| ▸ | PRKCA | P17252 | 5/20 | 0.49 |
| ▸ | FLT3 | P36888 | 2/20 | 0.49 |
| ▸ | PRKCB | P05771 | 1/20 | 0.49 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.39 |
| ▸ | HTR3B | O95264 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.39 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8966517 | 0.88 | PRKCQ (0.49) | ADRB2PRKCQPRKCDPRKCAFLT3 | |
| SCHEMBL22886936 | 0.88 | ADRB2 (0.47) | ADRB2PRKCQPRKCDPRKCAFLT3 | |
| SCHEMBL8966587 | 0.86 | PRKCQ (0.51) | ADRB2PRKCQPRKCDPRKCAFLT3 | |
| SCHEMBL9009948 | 0.84 | PRKCQ (0.54) | PRKCQPRKCDPRKCAFLT3PRKCB | |
| SCHEMBL8966454 | 0.83 | PRKCQ (0.68) | ADRB2PRKCQPRKCDPRKCAFLT3 | |
| SCHEMBL9010348 | 0.82 | PRKCQ (0.76) | PRKCQPRKCDPRKCAFLT3PRKCB | |
| SCHEMBL22412921 | 0.82 | PRKCQ (0.66) | PRKCQPRKCDPRKCAFLT3PRKCB | |
| SCHEMBL8966438 | 0.80 | PRKCQ (0.66) | ADRB2PRKCQPRKCDPRKCAFLT3 | |
| SCHEMBL11993709 | 0.78 | PRKCQ (0.45) | PRKCQPRKCDPRKCAFLT3PRKCB | |
| SCHEMBL22412919 | 0.77 | PRKCQ (0.58) | PRKCQPRKCDPRKCAFLT3PRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2020-09-17 | — | — | US | disclosed |
| US-20200282010-A1 | IMMUNOGENIC COMPOSITIONS AND USES THEREFOR | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2020-09-10 | — | — | US | disclosed |
| US-10736892-B2 | Stem cell modulation II | EpiAxis Therapeutics Pty Ltd. (AU) | 2020-08-11 | — | — | US | disclosed |
| US-20190192509-A1 | Stem Cell Modulation II | EpiAxis Therapeutics Pty Ltd. (AU) | 2019-06-27 | — | — | US | disclosed |
| US-20170266140-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2017-09-21 | — | — | US | disclosed |
| US-20170266140-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2017-09-21 | — | — | US | disclosed |
| US-20160354367-A1 | Stem Cell Modulation II | UNIVERSITY OF CANBERRA (AU) | 2016-12-08 | — | — | US | disclosed |
| US-20160354367-A1 | Stem Cell Modulation II | UNIVERSITY OF CANBERRA (AU) | 2016-12-08 | — | — | US | disclosed |
| US-8815866-B2 | Aminopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815866-B2 | Aminopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-26 | — | — | US | disclosed |
| US-8377926-B2 | Aminopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377926-B2 | Aminopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120214799-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214799-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-23 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188071-B2 | Amino substituted pyridines as potent kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110183966-A1 | AMINOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110183966-A1 | AMINOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214799-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | ADRB2 3758/4885PRKCQ 38/4885PRKCD 120/4885 |
| US-10736892-B2 | Stem cell modulation II | PRKCQ, PRKCI, PRKCG | ADRB2 2375/4885PRKCQ 1/4885PRKCD 9/4885 |
| US-20090124602-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | ADRB2 3758/4885PRKCQ 38/4885PRKCD 120/4885 |
| US-20170266140-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | PRKCQ, PRKCG, PRKCH | ADRB2 3892/4885PRKCQ 1/4885PRKCD 12/4885 |
| US-20200282010-A1 | IMMUNOGENIC COMPOSITIONS AND USES THEREFOR | NFATC1, PRKCQ, PRKCH | ADRB2 3790/4885PRKCQ 2/4885PRKCD 8/4885 |
| US-20200289437-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | PRKCQ, PRKCG, PRKCH | ADRB2 3892/4885PRKCQ 1/4885PRKCD 12/4885 |
| US-20190192509-A1 | Stem Cell Modulation II | PRKCQ, PRKCI, PRKCG | ADRB2 2375/4885PRKCQ 1/4885PRKCD 9/4885 |
| US-20110183966-A1 | AMINOPYRIDINE KINASE INHIBITORS | MAP3K5, MAP3K20, MAP4K5 | ADRB2 1742/4885PRKCQ 37/4885PRKCD 85/4885 |
| US-20160354367-A1 | Stem Cell Modulation II | PRKCQ, PRKCI, PRKCG | ADRB2 2375/4885PRKCQ 1/4885PRKCD 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.